相关实验视频

Updated: Jun 11, 2025

Author Spotlight: A Reproductive Hysteroscopy Approach for Complete Endometrial Polyp Removal and Enhanced Endometrial Receptivity

Author Spotlight: A Reproductive Hysteroscopy Approach for Complete Endometrial Polyp Removal and Enhanced Endometrial Receptivity

Published on: August 2, 2024

怀孕早期损失管理后的结果与米费普里斯顿加米索普罗斯托尔与单独的米索普罗斯托尔相比

Lyndsey S Benson¹, Navya Gunaje², Sarah K Holt²

¹Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle.

JAMA network open

|October 8, 2024

概括

对于早期妊娠损失 (EPL) 的米费普里斯顿和米索普罗斯托尔组合疗法未得到充分利用,但减少了后续手术和急诊的需要. 这一发现表明,增加对mifepristone的获取可能会降低医疗保健成本.

科学领域:

生殖健康生殖健康
药理干预药理干预
医疗保健服务研究医疗服务研究

背景情况:

早期妊娠损失 (EPL) 的药物管理通常涉及mizoprostol,有或没有mifepristone预治疗.
米费普里斯顿加米索普罗斯托尔的组合比单独的米索普罗斯托尔更有效,但在美国未得到充分利用.

研究的目的:

为了比较早期妊娠损失 (EPL) 管理的临床结果,使用米费普里斯顿加米索普罗斯托尔与单独使用米索普罗斯托尔.
分析后续程序管理,复诊,住院和诊断后六周内并发症的差异.

主要方法:

从2015年10月1日到2022年12月31日,使用国家保险索赔数据 (IBM MarketScan研究数据库) 的回顾性队列研究.
包括15-49岁的私人保险患者,被诊断患有EPL,并接受药物管理.
主要暴露是药物治疗方案 (米费普里斯顿加米索普罗斯托尔与单独的米索普罗斯托尔);主要结局是随后的程序管理.

主要成果:

这项研究包括31,977名患者;只有3.0%的患者接受了米费普里斯加米索普罗斯托.
接受米费普里斯顿加米索普罗斯托尔的患者不太可能接受随后的子宫吸血 (10.5%vs14.0%),并因EPL而访问急诊室 (3.5%vs7.9%).
多变量分析表明,米费普里斯的使用与随后程序管理的几率下降有关 (aOR,0.71).

结论:

在美国,米费普里斯在早期妊娠损失 (EPL) 管理中未得到充分利用.
米费普里斯顿和米索普罗斯托尔的组合与减少对子宫吸血的需求和减少急诊室访问有关.
扩大用于EPL管理的Mifepristone的获取范围可能会降低医疗保健利用率和相关支出.

更多相关视频

Introduction of Intracapsular Rotary-cut Procedures IRCP: A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation

Introduction of Intracapsular Rotary-cut Procedures IRCP: A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation

Published on: January 17, 2019

Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage

Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage

Published on: August 4, 2021

相关概念视频

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Ovarian Cycle

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...

Birth Control Methods

Birth Control Methods

Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although...